Stoke Therapeutics
STOK | NASDAQ
$26.63
-$0.05 (-0.19%)
At close: Nov 16, 2026, 4:00 PM ET
$26.63
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Stoke Therapeutics Company Profile
Company profile explainedCompany Profile
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Ian F. Smith | Chief Executive Officer & Director |
| Sara Den Besten | Chief People Officer |
| Thomas Edward Leggett | Chief Financial Officer |
| Adrian R. Krainer | Co-Founder & Independent Director |
| Barry S. Ticho FACC | Chief Medical Officer |
| Edward Kaye | Advisor & Director |
| Isabel Aznarez | Co-Founder & CTO |
| Jason Hoitt | Chief Patient Officer |
| Jonathan Allan | Corporate Secretary, Compliance Officer & General Counsel |
| Susan Willson | Vice President of Corporate Communications |
| Thomas McCauley | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 30, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 25, 2026 | 4 | Filing |
| Sep 25, 2026 | 3 | Filing |
| Sep 25, 2026 | 8-K | Current Report |
| Sep 03, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
Stoke Therapeutics
| Country | United States |
| IPO Date | Jun 19, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 170 |
| CEO | Ian F. Smith |
Contact Details
45 Wiggins Avenue Bedford,
Massachusetts 01730 United States
Stock Details
| Ticker Symbol | STOK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001623526 |
| CUSIP Number | 86150R107 |
| ISIN Number | US86150R1077 |
| SIC Code | 2834 |
Recent News
- 18 days ago / seekingalpha.comStoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript
- 18 days ago / marketbeat.comStoke Therapeutics Q3 Earnings Call Highlights
- 18 days ago / zacks.comStoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
- 28 days ago / seekingalpha.comStoke Therapeutics: The Market Misread A Key FDA Win
- 1 month ago / businesswire.comStoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
- 2 months ago / businesswire.comStoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
- 2 months ago / gurufocus.comStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
- 3 months ago / benzinga.comThese Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results
- 3 months ago / seekingalpha.comStoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
- 4 months ago / zacks.comStoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Add to Watchlist
Select watchlists to add or remove STOK